作者
Marta Cheli,John Vissing,Sithara Ramdas,Voháňka Stanislav,Maria Bonaria Uccheddu,Allard Lutgarde,Anthony Béhin,Elena Cortés‐Vicente,Anna Kostera‐Pruszczyk,Anna Rostedt Punga,Nils Erik Gilhus,Andreas Meisel,Lorenzo Maggi
摘要
Myasthenia Gravis is a potentially life-threatening autoimmune disease of the neuromuscular junction with fluctuating muscle weakness and fatigability. In recent years, the therapeutic landscape has been notably reshaped by the introduction of new therapies. These agents, primarily acting through complement inhibition or neonatal Fc-receptor blockade, have demonstrated significant efficacy and favorable safety profiles in randomized clinical trials and real-world settings. Their advent has refined clinical management, particularly in refractory patients, leading to meaningful improvements in patients' quality of life and future expectations. Meanwhile, in this evolving therapeutic landscape, new challenges and uncertainties in clinical decision-making have been raised, as new therapies are now part of the standard care in Myasthenia Gravis. Differences in regulatory agency approvals and reimbursement policies across Europe result in heterogeneous access to therapies, complicating treatment decisions and limiting shared real-world experiences. Consequently, clinicians face complex dilemmas regarding optimal patient selection, treatment choice, and long-term management strategies. To address these issues, a panel of experts, including adult and pediatric neurologists and patient representatives, within the framework of the European Reference Network for Neuromuscular Diseases convened to develop consensus-based positions. The aim of this work was to identify, explore, and discuss key challenges associated with the use of new therapies and to propose a practical approach to support clinicians in this rapidly evolving field. Given the variability in clinical approach, treatment availability and reimbursement policies across European healthcare systems, this position paper seeks to provide guidance that are adaptable across diverse settings. A literature review was conducted, focusing on pivotal clinical trials and real-world evidence. Eleven key topics were identified and discussed, and for each, consensus statements were developed and refined through a modified Delphi process: patient assessment from both clinician and patient perspectives; the role of autoantibodies and optimization of serological testing; selection of immunotherapies; definitions of treatment response and failure in the context of new therapies; strategies for switching between therapies; predictors of treatment response; management of concomitant therapies, including corticosteroids and conventional immunosuppressant; discontinuation strategies; their potential role as early-line therapies; their applicability in ocular MG; and future therapeutic perspectives, including ongoing clinical trials. In conclusion, new therapies represent a major advance in Myasthenia Gravis care but also introduce significant complexity. This expert position paper provides a framework to support clinicians in decision-making and highlights the need for harmonized guidelines and further research to optimize their use in routine practice.